Company: KROS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001664710-25-000070
Chunk: 236

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 1
Chunk 236
---
 data):

14

THREE MONTHS ENDED JUNE 30,SIX MONTHS ENDED JUNE 30,2025202420252024Numerator:Net income (loss) attributable to common stockholders - basic and diluted$(30,696)$(45,257)$117,755 $(88,371)Denominator:Weighted-average shares of common stock outstanding - basic40,612,907 36,103,187 40,586,279 35,894,305 Effect of potentially dilutive stock options— — 433,710 — Effect of potentially dilutive employee stock purchase plan shares— — — — Effect of potentially dilutive restricted stock units— — 133,769 — Total potentially dilutive securities— — 567,479 — Weighted-average shares of common stock outstanding used to compute diluted net loss140,612,907 36,103,187 41,153,758 35,894,305 Net income (loss) per share of common stockBasic$(0.76)$(1.25)$2.90 $(2.46)Diluted$(0.76)$(1.25)$2.86 $(2.46)The Company excluded the following from the computation of diluted net income (loss) per share attributable to common stockholders as of June 30, 2025 and 2024 because including them would have had an anti-dilutive effect: THREE MONTHS ENDED JUNE 30,SIX MONTHS ENDED JUNE 30,2025202420252024RSU awards12,462 — 6,265 — Options to purchase common stock4,838,595 5,240,672 4,865,192 5,240,672 Employee stock purchase plan shares29,517 — 35,628 — Total4,880,574 5,240,672 4,907,085 5,240,672 

9. INCOME TAXES 

The Company calculates income taxes at each interim reporting period based on the estimated annual effective tax rate for the full year, adjusted for any discrete events which are recorded in the period they occur. Cumulative adjustments to the income tax provision are recorded in the interim reporting period in which a change in the estimated annual effective tax rate is determined. The Company’s income tax (provision) benefit and effective tax rate are presented